Biosimilar Education and Curriculum Material Updates for healthcare Professional

The Food and Drug Administration is seeking to update its biosimilar education and curriculum materials for healthcare professionals. The current materials are outdated due to recent regulatory efficiency progress, specifically regarding the removal of default comparative efficacy studies. These updates are necessary to reflect streamlined regulatory approaches and provide the scientific justification required to ensure the safety and efficacy of biosimilars. The primary goal of this initiative is to support the approval of more biosimilars and interchangeables by reducing the need for large clinical studies. By modernizing these educational resources, the agency aims to lower costs and increase patient access to these medications while improving overall uptake and acceptance within the healthcare community.